RU2014101492A - Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак - Google Patents

Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак Download PDF

Info

Publication number
RU2014101492A
RU2014101492A RU2014101492/10A RU2014101492A RU2014101492A RU 2014101492 A RU2014101492 A RU 2014101492A RU 2014101492/10 A RU2014101492/10 A RU 2014101492/10A RU 2014101492 A RU2014101492 A RU 2014101492A RU 2014101492 A RU2014101492 A RU 2014101492A
Authority
RU
Russia
Prior art keywords
chokα
cancer
expression
level
sample
Prior art date
Application number
RU2014101492/10A
Other languages
English (en)
Russian (ru)
Inventor
САНХУАН Хуан Карлос ЛАКАЛЬ
Original Assignee
Траслэшионал Кэнсэр Драгз Фарма, С.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Траслэшионал Кэнсэр Драгз Фарма, С.Л. filed Critical Траслэшионал Кэнсэр Драгз Фарма, С.Л.
Publication of RU2014101492A publication Critical patent/RU2014101492A/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/91Transferases (2.)
    • G01N2333/912Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205Phosphotransferases in general
    • G01N2333/9121Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2014101492/10A 2011-06-20 2012-06-20 Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак RU2014101492A (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP11382211 2011-06-20
EP11382211.8 2011-06-20
US201161507833P 2011-07-14 2011-07-14
US61/507,833 2011-07-14
EP11382294.4 2011-09-16
EP11382294 2011-09-16
PCT/EP2012/061790 WO2012175537A1 (en) 2011-06-20 2012-06-20 Method for predicting the clinical response to chemotherapy in a subject with cancer

Publications (1)

Publication Number Publication Date
RU2014101492A true RU2014101492A (ru) 2015-07-27

Family

ID=47422050

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014101492/10A RU2014101492A (ru) 2011-06-20 2012-06-20 Способ прогнозирования клинического ответа на химиотерапию у субъекта, имеющего рак

Country Status (11)

Country Link
US (1) US20150004252A1 (enExample)
EP (1) EP2721174A1 (enExample)
JP (1) JP2014527397A (enExample)
KR (1) KR20140047664A (enExample)
CN (1) CN103687964A (enExample)
AU (1) AU2012274156A1 (enExample)
BR (1) BR112013032857A2 (enExample)
CA (1) CA2840129A1 (enExample)
MX (1) MX2013015286A (enExample)
RU (1) RU2014101492A (enExample)
WO (1) WO2012175537A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
WO2017188694A1 (ko) * 2016-04-25 2017-11-02 이뮤노메트테라퓨틱스 인코포레이티드 질소를 포함하는 헤테로아릴 화합물 및 이의 용도
EP3487857B1 (en) * 2016-07-25 2021-09-01 Nerviano Medical Sciences S.r.l. Purine and 3-deazapurine analogues as choline kinase inhibitors
US11339447B2 (en) 2017-03-29 2022-05-24 Crown Bioscience, Inc. (Taicang) System and method for determining Kareniticin sensitivity on cancer
CN107050668B (zh) * 2017-06-09 2020-03-31 南京医科大学第一附属医院 基于云处理的放疗效果预测方法
EP3502700A1 (en) * 2017-12-21 2019-06-26 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Methods based on the detection of rad51 foci in tumor cells
CN116859058A (zh) * 2023-07-17 2023-10-10 上海中医药大学 一种基于NDR1-Myc互作抗结直肠癌活性分子筛选方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ES2237332B1 (es) 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
KR101322705B1 (ko) * 2005-04-13 2013-10-29 꼰세호 수페리올 인베스띠가시오네스 시엔띠피까스 콜린 키나아제 베타를 유도하는 의약 조성물
GB0519405D0 (en) * 2005-09-23 2005-11-02 Univ Aberdeen Cancer therapy prognosis and target
EP2316970A2 (en) * 2008-07-04 2011-05-04 Traslational Cancer Drugs Pharma, S.L. Methods for the treatment and diagnosis of cancer
JP5764730B2 (ja) 2008-09-10 2015-08-19 ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー 1個だけで標識された多種類のプローブを用いるmRNA単一分子の画像化
US20100068302A1 (en) 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer

Also Published As

Publication number Publication date
CA2840129A1 (en) 2012-12-27
WO2012175537A1 (en) 2012-12-27
CN103687964A (zh) 2014-03-26
US20150004252A1 (en) 2015-01-01
KR20140047664A (ko) 2014-04-22
AU2012274156A1 (en) 2014-01-23
EP2721174A1 (en) 2014-04-23
BR112013032857A2 (pt) 2017-01-24
JP2014527397A (ja) 2014-10-16
MX2013015286A (es) 2014-09-25

Similar Documents

Publication Publication Date Title
Chen et al. Aquaporin 3 promotes epithelial-mesenchymal transition in gastric cancer
He et al. CTHRC1 induces non-small cell lung cancer (NSCLC) invasion through upregulating MMP-7/MMP-9
Nie et al. Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer
Koh et al. Prognostic impact of C-reactive protein/albumin ratio on the overall survival of patients with advanced nonsmall cell lung cancers receiving palliative chemotherapy
Shen et al. miR-590-5p regulates gastric cancer cell growth and chemosensitivity through RECK and the AKT/ERK pathway
Raz et al. Hedgehog signaling pathway molecules and ALDH1A1 expression in early-stage non-small cell lung cancer
Ni et al. Cortactin promotes colon cancer progression by regulating ERK pathway
Kinny-Köster et al. Favorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9
Pan et al. Targeted TPX2 increases chromosome missegregation and suppresses tumor cell growth in human prostate cancer
Liu et al. TPX2 as a novel prognostic biomarker for hepatocellular carcinoma
Zhang et al. Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway
Yun et al. High expression of transforming acidic coiled coil-containing protein 3 strongly correlates with aggressive characteristics and poor prognosis of gastric cancer
Wang et al. MicroRNA-10b is upregulated and has an invasive role in colorectal cancer through enhanced Rhoc expression
US20180095070A1 (en) Compositions and methods for prognosis and treatment of neoplasm
Li et al. S100A8+ stroma cells predict a good prognosis and inhibit aggressiveness in colorectal carcinoma
Li et al. Low expression of AIM2 combined with high expression of p-STAT3 is associated with poor prognosis in hypopharyngeal squamous cell carcinoma
Jiang et al. STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway Corrigendum in/10.3892/or. 2020.7855
Zhu et al. Prognostic value of ribonucleotide reductase subunit M1 (RRM1) in non-small cell lung cancer: A meta-analysis
Shen et al. MIR155HG knockdown inhibited the progression of cervical cancer by binding SRSF1
Roh et al. Phosphorylated 4E-binding protein 1 expression is associated with poor prognosis in small-cell lung cancer
Zhao et al. Cortactin is a sensitive biomarker relative to the poor prognosis of human hepatocellular carcinoma
Lin et al. Polo-like kinase 3 is associated with poor prognosis and regulates proliferation and metastasis in prostate cancer
Zhang et al. HSPA6, a novel prognostic and therapeutic biomarker, associated with Ming classification in gastric cancer
Liu et al. Elevated expression of Thoc1 is associated with aggressive phenotype and poor prognosis in colorectal cancer
Yuan et al. Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer Corrigendum in/10.3892/or. 2025.8976

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20170911